The strikingly higher SFRP4 expression in ERG positive (>30% with strong SFRP4 positivity) than in ERG negative cancers (<15% with strong SFRP4 positivity) could be explained by the transcriptional activation of ERG and its direct target EZH2 [53], known reported as the upstream regulator of SFRP4 [54]. This evidence concerns the gene EZH2 and cancer.